Shirley R. Kuhlmann - 10 Feb 2023 Form 4 Insider Report for COLLEGIUM PHARMACEUTICAL, INC (COLL)

Signature
/s/ Shirley R. Kuhlmann
Issuer symbol
COLL
Transactions as of
10 Feb 2023
Transactions value $
-$1,229,510
Form type
4
Date filed
14 Feb 2023, 16:18
Previous filing
16 Sep 2022
Next filing
28 Jun 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction COLL Common Stock Award $0 +48.1K +43.95% $0.00 158K 10 Feb 2023 Direct F1
transaction COLL Common Stock Award +25.7K +16.33% 183K 10 Feb 2023 Direct F2
transaction COLL Common Stock Tax liability -$436K -16.3K -8.88% $26.75 167K 10 Feb 2023 Direct F3
transaction COLL Common Stock Tax liability -$207K -7.76K -4.64% $26.75 159K 10 Feb 2023 Direct F4
transaction COLL Common Stock Sale -$586K -21.8K -13.69% $26.88 138K 13 Feb 2023 Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2024, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock.
F2 Effective February 10, 2023, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to an aggregate of 25,739 performance share units granted in the issuer's three prior fiscal years.
F3 Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.
F4 Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of performance stock units.
F5 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 28, 2022.
F6 The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.485 to $27.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6).